Mavoglurant Effective Against Cocaine Addiction in Phase 2 Trial
The drug company, Novartis, reports a significant decline in cocaine use with mavoglurant in phase 2 trial.
Dr. Anna Lembke on Using GLP-1 Drugs to Treat Addiction
Stanford University psychiatrist, Dr. Anna Lembke, assesses the use of GLP-1 drugs for treating addictions.
Remote Interventions Crush Relapse Rates in NIHR Study
Adding remote interventions to the standard treatment dramatically reduces relapse rates for substance use disorders.
How Oregon Helps Drug Addicts Recover
The Guardian’s Sam Levin shows how housing is the key to addiction recovery in Oregon.
The Medial Habenula and Addiction
A trio of studies look at the medial habenula, a region in the brain associated with addiction, depression, and compulsive behavior.
The Impact of GLP-1 Drugs on Reward Pathways
We examine the impact of GLP-1 drugs such as Ozempic on reward pathways and the dopamine system.